Study on the Regulation Effect of Optogenetic Technology on LFP of the Basal Ganglia Nucleus in Rotenone-Treated Rats.
Journal
Neural plasticity
ISSN: 1687-5443
Titre abrégé: Neural Plast
Pays: United States
ID NLM: 100883417
Informations de publication
Date de publication:
2021
2021
Historique:
received:
18
03
2021
accepted:
28
06
2021
entrez:
9
8
2021
pubmed:
10
8
2021
medline:
21
1
2022
Statut:
epublish
Résumé
Parkinson's disease (PD) is a common neurological degenerative disease that cannot be completely cured, although drugs can improve or alleviate its symptoms. Optogenetic technology, which stimulates or inhibits neurons with excellent spatial and temporal resolution, provides a new idea and approach for the precise treatment of Parkinson's disease. However, the neural mechanism of photogenetic regulation remains unclear. In this paper, we want to study the nonlinear features of EEG signals in the striatum and globus pallidus through optogenetic stimulation of the substantia nigra compact part. Rotenone was injected stereotactically into the substantia nigra compact area and ventral tegmental area of SD rats to construct rotenone-treated rats. Then, for the optogenetic manipulation, we injected adeno-associated virus expressing channelrhodopsin to stimulate the globus pallidus and the striatum with a 1 mW blue light and collected LFP signals before, during, and after light stimulation. Finally, the collected LFP signals were analyzed by using nonlinear dynamic algorithms. After observing the behavior and brain morphology, 16 models were finally determined to be successful. LFP results showed that approximate entropy and fractal dimension of rats in the control group were significantly greater than those in the experimental group after light treatment ( Optogenetic technology can regulate the characteristic value of LFP signals in rotenone-treated rats to a certain extent. Approximate entropy and fractal dimension algorithm can be used as an effective index to study LFP changes in rotenone-treated rats.
Sections du résumé
Background
Parkinson's disease (PD) is a common neurological degenerative disease that cannot be completely cured, although drugs can improve or alleviate its symptoms. Optogenetic technology, which stimulates or inhibits neurons with excellent spatial and temporal resolution, provides a new idea and approach for the precise treatment of Parkinson's disease. However, the neural mechanism of photogenetic regulation remains unclear.
Objective
In this paper, we want to study the nonlinear features of EEG signals in the striatum and globus pallidus through optogenetic stimulation of the substantia nigra compact part.
Methods
Rotenone was injected stereotactically into the substantia nigra compact area and ventral tegmental area of SD rats to construct rotenone-treated rats. Then, for the optogenetic manipulation, we injected adeno-associated virus expressing channelrhodopsin to stimulate the globus pallidus and the striatum with a 1 mW blue light and collected LFP signals before, during, and after light stimulation. Finally, the collected LFP signals were analyzed by using nonlinear dynamic algorithms.
Results
After observing the behavior and brain morphology, 16 models were finally determined to be successful. LFP results showed that approximate entropy and fractal dimension of rats in the control group were significantly greater than those in the experimental group after light treatment (
Conclusion
Optogenetic technology can regulate the characteristic value of LFP signals in rotenone-treated rats to a certain extent. Approximate entropy and fractal dimension algorithm can be used as an effective index to study LFP changes in rotenone-treated rats.
Identifiants
pubmed: 34367273
doi: 10.1155/2021/9938566
pmc: PMC8342173
doi:
Substances chimiques
Uncoupling Agents
0
Rotenone
03L9OT429T
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
9938566Informations de copyright
Copyright © 2021 Zongya Zhao et al.
Déclaration de conflit d'intérêts
The authors declare that they have no competing interests.
Références
Mol Cell Neurosci. 2018 Apr;88:70-82
pubmed: 29414104
Psychol Med. 2017 Oct;47(13):2302-2311
pubmed: 28374660
Parkinsons Dis. 2017;2017:9641392
pubmed: 28280646
Behav Brain Res. 2016 May 15;305:258-64
pubmed: 26970579
Neurosci Lett. 2018 Jan 18;664:51-57
pubmed: 29128628
Neurology. 2005 Jan 25;64(2):224-9
pubmed: 15668417
Mov Disord. 2007 Jun 15;22(8):1077-92
pubmed: 17394234
Exp Neurol. 2013 Jul;245:52-9
pubmed: 22921537
Prog Neurobiol. 2000 Sep;62(1):63-88
pubmed: 10821982
Mov Disord. 2017 Apr;32(4):530-537
pubmed: 28256089
Dement Geriatr Cogn Disord. 2008;26(3):218-25
pubmed: 18781072
Curr Opin Neurol. 2013 Dec;26(6):662-70
pubmed: 24150222
Parkinsonism Relat Disord. 2018 May;50:54-60
pubmed: 29472099
Brain Res Brain Res Rev. 2005 Dec 15;50(2):336-60
pubmed: 16278019
J Neurol. 2000 Apr;247 Suppl 2:II19-24
pubmed: 10991661
Neuropharmacology. 2005 Jun;48(7):984-92
pubmed: 15857625
Curr Psychiatry Rep. 1999 Oct;1(1):61-8
pubmed: 11122906
Neurol Ther. 2021 Jun;10(1):7-30
pubmed: 33140286
Annu Rev Neurosci. 2000;23:185-215
pubmed: 10845063
Curr Neuropharmacol. 2019;17(2):165-175
pubmed: 29512464
Clin Neuropharmacol. 2012 Nov-Dec;35(6):266-8
pubmed: 23123688
Neuroscience. 2017 Oct 11;361:144-156
pubmed: 28823819
Neurosurgery. 2010 Oct;67(4):N28-9
pubmed: 20881550
Neuroscience. 2019 Apr 15;404:27-38
pubmed: 30790668
J Neurol Neurosurg Psychiatry. 2016 Jul;87(7):717-21
pubmed: 26424898
J Exp Pharmacol. 2018 Jul 04;10:29-35
pubmed: 30013404
Exp Neurol. 2004 Oct;189(2):369-79
pubmed: 15380487
Neuropharmacology. 2012 Jan;62(1):115-24
pubmed: 21903105
Neurobiol Dis. 2013 Jun;54:464-74
pubmed: 23388190
ACS Chem Neurosci. 2018 Apr 18;9(4):762-772
pubmed: 29226687
Am J Alzheimers Dis Other Demen. 2013 Mar;28(2):154-64
pubmed: 23271331
Prog Brain Res. 2020;252:525-557
pubmed: 32247374
Front Behav Neurosci. 2018 Aug 27;12:185
pubmed: 30210317
Neuroscience. 2017 Mar 14;345:297-314
pubmed: 27235739
Neuropharmacology. 2012 Jun;62(7):2154-68
pubmed: 22361232
Clin Neuropharmacol. 2016 Nov/Dec;39(6):302-305
pubmed: 27755134
Neurodegener Dis. 2010;7(1-3):112-5
pubmed: 20173339
Mov Disord. 2017 Jun;32(6):893-903
pubmed: 28370447
J Neural Transm (Vienna). 2018 Aug;125(8):1137-1144
pubmed: 29242978
Neurosci Lett. 2017 Jan 1;636:95-100
pubmed: 27818350
Parkinsonism Relat Disord. 2017 Mar;36:63-68
pubmed: 28108263
Clin Neuropharmacol. 2004 Nov-Dec;27(6):270-3
pubmed: 15613930
Stereotact Funct Neurosurg. 2018;96(1):22-32
pubmed: 29444523
Exp Neurol. 2016 Dec;286:124-136
pubmed: 27743915
Curr Gene Ther. 2018;18(1):40-44
pubmed: 29512463
Ann Neurol. 2013 Sep;74(3):449-57
pubmed: 23852650
Brain Res. 2017 Jan 15;1655:104-113
pubmed: 27876560
Neuropharmacology. 2011 Sep;61(4):753-60
pubmed: 21635907
Curr Biol. 1996 Apr 1;6(4):368-71
pubmed: 8723334
J Neurol Sci. 2015 Jan 15;348(1-2):231-40
pubmed: 25542079
Lancet Neurol. 2017 Mar;16(3):238-250
pubmed: 28229895